Pharsight

Cresemba is owned by Astellas.

Cresemba contains Isavuconazonium Sulfate.

Cresemba has a total of 4 drug patents out of which 0 drug patents have expired.

Cresemba was authorised for market use on 06 March, 2015.

Cresemba is available in capsule;oral dosage forms.

Drug patent challenges can be filed against Cresemba from 2026-03-06.

The generics of Cresemba are possible to be released after 14 September, 2027.

Application	Filing Date	Opposition Party	Legal Status
EP07802308A	2010-12-03	Basilea Pharmaceutica International AG	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6812238	ASTELLAS	N-substituted carbamoyloxyalkyl-azolium derivatives	Oct, 2025 (2 years from now)
US10812238	ASTELLAS	Configurable reference signals	Oct, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206879	ASTELLAS	Active ingredient containing stabilised solid forms and method for the production thereof	Sep, 2027 (4 years from now)
US10603280	ASTELLAS	Active ingredient containing stabilised solid medicinal forms and methods for the production thereof	Sep, 2027 (4 years from now)

Do you want to check out CRESEMBA patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 6, 2020
ODE* (ODE*)	Mar 6, 2022
Orphan Drug Exclusivity (ODE)	Mar 6, 2022
Generating Antibiotic Incentives Now (GAIN)	Mar 6, 2027